Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary, Sapu Nano, will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation highlights findings on tissue concentration-driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics, underscoring the importance of tissue-level drug distribution in determining toxicity profiles.
The data support the development of improved delivery strategies, including intravenous and nanoparticle-based formulations, which could enhance the therapeutic index of everolimus and other drugs. This research represents a significant step toward understanding how drug localization within tissues influences safety and efficacy, potentially leading to more targeted and less toxic cancer therapies.
Everolimus is an mTOR inhibitor used in oncology, but its clinical utility is limited by systemic toxicity. By examining drug concentrations directly in tissues, Sapu Nano's work aims to identify organ-specific risks and optimize dosing regimens. The findings could pave the way for nanomedicine platforms that deliver drugs more precisely to tumors while sparing healthy tissues.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. Oncotelic, through its wholly owned subsidiary Sapu, is seeking to leverage its expertise in oncology drug development to improve treatment outcomes for cancer patients, with a special emphasis on rare pediatric cancers.
Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia (AML) through OXi 4503. The company also acquired PointR Data Inc. in November 2019 to build an AI-driven biotechnology company and acquired AL-101 for intranasal delivery of apomorphine to treat Parkinson's disease and other disorders.
For more information on the upcoming presentation, visit the full press release at https://ibn.fm/kZzE3. For the latest news and updates on Oncotelic, visit the company’s newsroom at https://ibn.fm/OTLC.
